The efficacy and safety of methsuximide (MSM) was evaluated in children with intractable epilepsies in a prospective uncontrolled study.
INTRODUCTION
In 1951 methsuximide (Celontin , Petinutin ) was found to be an antiepileptic agent when Chen 1 and Miller 2, 3 tested several succinimides for their seizure inhibiting properties. After its introduction in the United States in 1957 it became a widely used drug, mainly (but not only) for the control of absence seizures 4 . However, its use declined after ethosuximide was shown to be even more effective and less toxic in absences. Currently the use of MSM is restricted to epilepsy centres, where it is used in combination with other established antiepileptic drugs (AED) for intractable epilepsies.
N-Desmethylmethsuximide is the active metabolite of methsuximide (MSM) and is found in the serum of patients taking MSM at levels 700 times greater than those of the parent drug 5 . The mechanisms of action of MSM are not known and are possibly multiple 6 . In combination therapy MSM raises the levels of phenobarbital, phenytoin and primidone significantly and lowers levels of carbamazepine and valproic acid 7, 8 .
Clinical studies show efficacy of MSM against absence seizures, juvenile myoclonic epilepsy, mixed epilepsies, Lennox-Gastaut syndrome and various other types of epilepsy [9] [10] [11] [12] (see Table 1 ). There is no prospective controlled study which shows efficacy of MSM in defined epileptic syndromes. Side effects described in patients under treatment with MSM are sedation, gastrointestinal disturbances, hiccups, ataxia, leukopenia and allergic rash 8 . Patients with MSM intoxication develop coma and respiratory depression 13 . No fatal outcome has been published yet. Of the 17 studies of MSM listed in Table 1 , only three studies focused on the use of MSM in children 9, 11, 14 . Most of the studies are difficult to interpret because of ill-defined and unspecified patient populations, seizure classifications and methods used for determining therapeutic success and plasma levels of Ndesmethylmethsuximide. Stenzel et al. 11 and Tennison et al. 14 reported good efficacy of MSM in epilepsies which were refractory to modern AED treatment.
At the Pediatric Hospital of the Bethel Epilepsy Centre, MSM is still used as a drug of further choice in epilepsies which are not controlled by treatment with standard AED. Since several new antiepileptic compounds have been introduced during the last two decades 15 it seemed interesting to analyse data of children on treatment with the 'old' drug MSM. We wanted to determine if MSM should still be considered in the treatment of epilepsies.
MATERIALS AND METHODS
Data were collected prospectively from 116 consecutive children in whom MSM treatment was started. Four patients were excluded from the study because neurometabolic or neurodegenerative disease was found to be the underlying cause for the seizures. Thus data of 112 patients were analysed.
Sixty-eight patients were male, 44 female. The mean age at onset of MSM therapy was 8.9 years (range 15 months to 20 years). The mean duration of epilepsy prior to consideration of MSM treatment was 6.4 years (range 12 months to 16 years). A mean of 5.3 other AED (SD 1.9) had been used in various combinations without satisfactory result. Prior to starting the MSM therapy, previous AED treatments and their related plasma levels had been reviewed. In cases of insufficient dosage, the drugs were re-administered until sufficient seizure control was achieved or side effects occurred without therapeutic success before administration of MSM was considered.
Forty of the 112 patients were classified as having a symptomatic focal epilepsy. Thirty-eight patients were diagnosed with Lennox-Gastaut syndrome consistent with the definition of Gastaut et al. 1966 16 . Other diagnoses included juvenile myoclonic epilepsy (n = 4), generalized cryptogenic (n = 4) or symptomatic epilepsy (n = 4), and West syndrome (n = 3).
The period during which the AED regimen was not altered before introduction of MSM (for a minimum of 2 weeks; average 3.7 weeks) was considered the baseline phase. At the beginning of the titration phase (mean duration 5.2 weeks) MSM was started with a single daily dose of about 5 mg kg −1 . The MSM dose was raised by increments of 3.2-5.5 mg kg −1 per week until sufficient seizure control was achieved or side effects were observed. During titration and treatment phases, serum concentrations of NDM and all co-administered AED were determined weekly by means of high performance liquid chromatography (HPLC) 17 . The ratio of N-desmethylmethsuximide serum concentrations and daily MSM doses were determined in order to evaluate the individual MSM metabolization rate.
For obtaining data on long-term outcome, parents, current caregivers, pediatricians and pediatric neurologists responsible for the antiepileptic treatment were interviewed by questionnaire and (if necessary) by telephone.
For determining the therapeutic effect of MSM we compared seizure frequency during the baseline phase and during the treatment phase (short-term) or with information on seizure frequency from the questionnaire (long-term). Accordingly, patients were classified into the following groups:
(I) greater than 50% decrease in seizure frequency, (II) no appreciable change (<50% decrease and <100% increase in seizure frequency), and (III) deterioration.
All patients with intolerable side effects were classified in group III without regard to possible reduction of seizure frequency.
RESULTS
A 50% or greater reduction in seizure frequency (group I) during short-term phase (mean 9.1 weeks) was obtained in 40 of the 112 patients (35.7%). Ten of these patients became seizure free (8.9%). Fortyseven patients did not show significant changes in their seizure frequency (group II) and 25 patients became worse (group III). Included in group III were those patients in whom side effects prompted a discontinuation of MSM administration (n = 12). Twenty-seven point 5 percent of the patients with symptomatic focal epilepsy (n = 11) showed a 50% or greater decrease in seizure frequency (group Ishort-term) compared to 39.5% of patients with Lennox-Gastaut syndrome (n = 15). Ten of the 40 patients with symptomatic focal epilepsy became worse when MSM was administered, whereas only five of the Lennox-Gastaut patients had to be classified in group III (deterioration).
Variance analysis of reduction of seizure frequency in relation to sex, age, epilepsy diagnosis, types of seizures, prior drug treatment and co-medication revealed no significant influence of any of these factors on therapeutic efficacy of MSM in our patient population.
At the time of discharge from the epilepsy Centre, 71 patients continued to take MSM as part of their medication. Fourteen patients were lost to follow up; thus follow up data were obtained in 57 patients.
When we re-evaluated the 57 patients after an average of 3.7 years (range 18 months to 7.1 years) we found 39 still receiving MSM, of whom 22 (19.6% of all 112 patients) continued to benefit from the drug (greater than 50% decrease in seizure frequency compared with baseline and absence of intolerable side effects). Six of 38 patients with Lennox-Gastaut syndrome and 7 of 40 patients with symptomatic focal epilepsies were classified in group I on reviewing long-term outcome of patients on MSM.
The mean effective NDM plasma concentration of patients in group I was 36.0 mg l −1 (SD 6.2). No seizure inhibiting effect of MSM was documented in children with N-desmethylmethsuximide plasma levels below 25 mg l −1 . Plasma levels of all coadministered AED were within normal range during treatment phase.
Side effects occurred in 41 of the 112 patients (28.9%) while taking MSM (Table 2 ). In 12 of these children MSM administration had to be discontinued due to side effects. All side effects were completely reversible after removal of MSM from the therapeutic regimen or by temporary lowering of the daily dose of MSM. There was no association of a particular side effect with one of the co-administered AED. a The number of patients in whom this particular side effect prompted a discontinuation of MSM treatment.
Ataxia and leukopenia were only documented with corresponding N-desmethylmethsuximide plasma levels higher than 45 mg l −1 . No serious idiosyncratic, hepatic, or renal toxicity occurred.
Metabolism of MSM appeared to be correlated with age in a nonlinear fashion (Figure 1 ). Thus younger children need higher doses of MSM compared to older children to reach the same plasma levels of Ndesmethylmethsuximide. This effect was found to be independent of sex, epilepsy diagnosis, therapeutic effect of MSM and of the occurrence and type of side effects.
DISCUSSION
After several years of unsatisfactory trials to control seizures with various combinations of different substances an additional AED is not very likely to cause dramatic improvement in the outcome of a child with the types of epilepsy we saw in our patient population. Every possible effort must still be made to control or at least to reduce the frequency of seizures in these patients.
Compared with AED which have shown similar efficacy and safety, little has been published on MSM and consequently little may be known about its use especially in children. On analysing data of the 'intractable' patients who were treated with MSM at the Bethel Centre we found MSM not only to be effective, reducing seizure frequencies in an uncontrolled prospective study, but also safe; no serious or irreversible toxicity occurred.
In contrast to reports on adult patients, in whom plasma levels of the active metabolite Ndesmethylmethsuximide of 10-30 8 or 10-40 mg l −15 were reported to be effective, we found in children the therapeutic range of the metabolite to be as high as 25-45 mg l −1 . No therapeutic effect of MSM was seen in children with N-desmethylmethsuximide serum concentrations below 25 mg l −1 whereas no signs of toxicity occurred with corresponding plasma levels of less than 45 mg l −1 . The median side effect rate of 16 of the 17 previous studies on MSM listed in Table 2 was 36% (mean 39.2%). With a rate of 28.9% relatively few of our patients developed side effects. This could be due to the fact that only three of the 17 studies 8, 14, 18 considered serum concentrations and interactions of Ndesmethylmethsuximide and other AED. Thus a good part of the side effects seen in other studies were possibly caused by high or toxic plasma levels of antiepileptic substances.
Leukopenia (n = 2) and ataxia (n = 4) occurred only when N-desmethylmethsuximide plasma levels exceeded 45 mg l −1 , suggesting that these findings in patients on MSM may be signs of toxic plasma levels of the metabolite rather than side effects.
When using MSM, it is important to consider its interaction with other AED such as phenytoin, primidone and phenobarbital (rise in plasma levels) or carbamazepine and valproic acid (decrease in plasma level). Furthermore, MSM dosages should be increased slowly to prevent the occurrence of gastrointestinal disturbances 19 . Plasma levels of MSM and coadministered antiepileptic compounds should be monitored at least weekly during titration and for the first 2 weeks of the treatment phase.
While newer anticonvulsant compounds are being investigated for their efficacy and toxicity we investigated one of the old and almost forgotten AED. We come to the conclusion that MSM is a drug with long record and low toxicity that is potentially useful as an 'add-on' drug in intractable epilepsies-especially in Lennox-Gastaut syndrome and in symptomatic focal epilepsies before considering surgery.
